LTBK-01. MUTANT IDH INHIBITORS INDUCE LINEAGE DIFFERENTIATION IN IDH-MUTANT OLIGODENDROGLIOMA. (19th November 2021)

• Record Type: Journal Article
• Authors: Spitzer, Avishay; Gritsch, Simon; Weisman, Hannah R; Castro, L Nicolas Gonzalez; Chanoch, Rony; Lee, Christine K; Nagashima, Hiroaki; Miller, Julie J; Arrillaga-Romany, Isabel; Louis, David N; Wakimoto, Hiroaki; Pisano, Will; Wen, Patrick Y; Ligon, Keith L; Cahill, Daniel P; Suvà, Mario L; Tirosh, Itay
• Is Part Of: Neuro-oncology. Volume 23: Supplement 6(2021)
• Page Start: vi230
• Page End: vi230
• Publication Date: 2021-11-19
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab196.924
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Recent data showed promising signs of objective tumor responses in subsets of patients with low grade glioma treated with inhibitors of mutant IDH (IDHi). However, the molecular and cellular underpinnings of such responses are not known. Here, we profiled 6, 039 transcriptomes by single-cell or single-nucleus RNA-sequencing isolated from three IDH-mutant oligodendroglioma patients with clinical response to IDHi. Importantly, the tissues were sampled on-drug, four weeks from treatment initiation and our dataset includes a matched pre- and on-treatment sample pair. We integrate our findings with analysis of 8, 241 transcriptomes from seven untreated samples, 134 bulk samples from the TCGA and experimental models. We find that IDHi treatment induces a robust lineage differentiation towards an astrocytic-like cellular state accompanied by a depletion of stem-like cells and a reduction of cell proliferation. Our study provides the first evidence in patients of the differentiating potential of IDHi on the cellular hierarchies that drive oligodendrogliomas.